Johnson & Johnson and Genmab announced program discontinuations over the holiday period. J&J terminated a phase 2b atopic dermatitis study of JNJ‑95475939 after an interim analysis failed to meet predefined efficacy thresholds. Genmab halted development of acasunlimab, a PD‑L1x4‑1BB bispecific, citing portfolio strategy. Both companies emphasized pipeline prioritization and will reallocate resources to higher‑value or higher‑probability programs. The moves remove late‑stage uncertainty around these specific candidates and underscore ongoing portfolio rationalization across big pharma.